Promises and challenges of positron emission tomography for assessment of sarcoma in daily clinical practice. by Luijtgaarden, A.C.M. van de et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/71333
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Cancer Imaging (2008) 8, S61S68
DOI: 10.1102/1470-7330.2008.9011
MINI-SYMPOSIUM: IMAGING TECHNIQUES FOR ASSESSING
TREATMENT RESPONSE
Tuesday 7 October 2008, 09:0010:30
Promises and challenges of positron emission
tomography for assessment of sarcoma in
daily clinical practice
A.C.M. van de Luijtgaardena, J.W.J. de Rooyc, L.F. de Geus-Oeib,
W.T.A. van der Graafa and W.J.G. Oyenb
aDepartment of Medical Oncology, bDepartment of Nuclear Medicine and cDepartment of Radiology,
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Corresponding address: W.J.G. Oyen, MD, PhD, Department of Nuclear Medicine (444),
PO Box 9101, 6500 HB Nijmegen, The Netherlands.
Email: w.oyen@nucmed.umcn.nl
Abstract
A correct histological diagnosis, careful staging and detection of tumour response to treatment are all crucial in the
management of sarcomas. Imaging is important in all of these stages. Sarcomas have distinct biological and treatment-
related features posing challenges for imaging. For example, size measurements may not adequately reflect response
rates. Techniques which can measure tissue function rather than generate merely anatomical data such as positron
emission tomography (PET) are rapidly gaining interest. We discuss the importance of imaging in different stages
of patient management, emphasising the unique characteristics of sarcoma. Furthermore, we discuss the potential of
PET for the various indications, focussing on therapy evaluation.
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Introduction
Sarcomas are a rare and heterogeneous group of
mesenchymal-derived tumours with distinct molecular
features. They are subclassified into bone and soft-
tissue sarcoma (STS). The latter group consists of over
50 subtypes including gastro-intestinal stromal tumour
(GIST)[1]. In STS, treatment consists of surgery and in
selected subtypes or stages of disease also of radiotherapy
and/or chemotherapy. In bone sarcoma, such as Ewings
sarcoma and osteosarcoma, treatment always includes
(neo-)adjuvant chemotherapy. Targeting underlying
molecular events may provide spectacular benefits, as
demonstrated in GIST and dermatofibrosarcoma protu-
berans (DFSP)[25]. Prognosis depends on the extent
of the disease, requiring optimal staging, and the possi-
bility for radical resection of the primary tumour.
Prognosis drops dramatically once the sarcoma is metas-
tasised or worsens, in case of Ewings sarcoma and osteo-
sarcoma, if the histological response to neoadjuvant
chemotherapy is limited. Early, adequate therapy evalua-
tion prevents prolonged exposure to toxic yet ultimately
unsuccessful treatment, which in some cases may be sub-
stituted by an alternative, more effective one. An ideal
evaluationmethod should provide information in an objec-
tive and reproducible fashion. At present, especially since
the introduction of targeted therapies, the call for func-
tional rather than mere anatomical imaging is increasing.
Diagnosis, grading and staging
Histological classification is a crucial first step in sus-
pected sarcomas since tumour type and grade have
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major impact on prognosis and management. The heter-
ogeneity of sarcomas poses the risk for sampling error
from a single biopsy while repeated biopsy risks tumour
spread. Currently, imaging of the primary tumour is
mainly performed by magnetic resonance imaging
(MRI) or computed tomography (CT), depending
on the tumour localisation. Both modalities provide
important anatomical information and have also been
used to assess tissue composition[68] to select the
biopsy site most likely to have the highest grade present.
Furthermore, local tissue reaction and invasion may give
an impression of the malignancy grade, which helps
avoiding false reassurance in non-representative biopsy.
Staging is also crucial, as the mainstay of therapy is rad-
ical surgery. In peripheral sarcomas limb-sparing surgery
is largely facilitated as MRI enables assessment of the
anatomical extension of the tumour, as well as its rela-
tionship with the neurovascular bundle and other adja-
cent structures. Still, large and disabling surgical
interventions are no exception. This is acceptable in the
setting of localised sarcoma but not in metastasised dis-
ease. CT is the imaging technique of choice to detect
pulmonary metastasis and [99mTc]polyphosphate bone
scintigraphy is useful to stage sarcomas allowing whole-
body screening for bone metastases[9] and  in bone-
forming sarcomas  soft-tissue metastases[10]. More
recently, whole-body MRI was found more sensitive
than bone scanning in the detection of osseous metasta-
ses from Ewings sarcoma[11]. The basis for these find-
ings is the intramedullary accumulation of tumour cells
replacing the normal marrow before reactive osteoblastic
response occurs. MRI directly reveals neoplastic bone
marrow infiltrates[11].
Response evaluation and restaging
Available imaging modalities for therapy evaluation are
essentially the same as in staging and grading[12,13] and
the choice is guided by tumour or metastasis localisation.
Bone scintigraphy, however, is not sufficiently specific
for assessment of response[14,15]. Much work has been
done to standardise the interpretation of radiological
evaluation methods on the basis of size. This resulted
in the World Health Organization (WHO) criteria[1618],
later replaced by the simplified European Organisation
for Research and Treatment of Cancer Response
Evaluation Criteria in Solid Tumours (EORTC/
RECIST)[1921]. These criteria have imperfections, both
in general and specifically for sarcoma. First, they were
originally based on the change in tumour size which
could reliably be detected by palpation[22]. Therefore
marked size reduction is required before a tumour is con-
sidered responsive to therapy. Although much smaller
changes can now be detected, these RECIST criteria
are still adhered to because of a supposed relationship
between tumour size reduction and clinical benefit. The
inter- and intratumoural heterogeneity and the rareness of
sarcomas have prevented a reliable scientific foundation
of the relationship between size and effects, although
there are several reasons to question whether such a rela-
tionship exists.
First, sarcomas differ from other tumours as they
contain large volumes of non-malignant cells and other
stromal materials, which maintain a certain size even
if all malignant components disappear[2325]. Also, with
the disappearance of tumour cells, rather than shrinkage,
replacement with fibrous materials or calcification can be
seen[26]. In bone sarcomas, surrounding bone has limited
capacity to return to its normal size (Fig. 2)[12]. In GIST,
progression under treatment may present as a nodule
within a cystic mass, instead of mass enlargement[27].
Finally, the development of targeted tyrosine kinase inhi-
bitors and antibodies[28] needs consideration. These treat-
ments are cytostatic rather than cytoreductive and hence
cause consolidation rather than reduction of tumour size.
In summary, the large changes in size required by
WHO and RECIST criteria may be too stringent for
the detection of progression or response in sarcoma.
Furthermore, size reduction takes time. Thus, identifica-
tion of tumour response  or lack thereof  may require
several weeks or months. This time delay causes unnec-
essary costs and toxicity and may prevent a timely
switch to alternative treatments. Moreover, the absence
of progression of disease is increasingly considered as a
relevant endpoint for clinical trials, replacing response
rate[5,29].
To overcome the possibility that size does not repre-
sent tumour viability, histological evaluation can be per-
formed. Histological evaluation for therapy-related
changes, including the percentage of necrosis, provides
adequate insight into the response to previous therapy
and correlates well with prognosis. Limitations are that
standardised approaches are only available for osteosar-
coma and Ewings sarcoma[30]. Heterogeneity of the
tumour might again hamper a representative and reliable
histological assessment based on small biopsies.
New developments
Improvements in anatomical imaging
and interpretation
The above-mentioned restrictions of anatomical imaging
during therapy are not only challenging for existing
criteria, they are also demanding for the development
of new ones. The appearance of a nodule within a
mass has been proposed as a sign of recurrent
GIST[27]. Choi and colleagues have shown that a 10%
tumour size decrease or 15% tumour density decrease as
determined by measuring the attenuation coefficient are
sensitive and specific methods for assessing targeted ther-
apy response in patients with GIST (the so-called Choi
criteria) (Fig. 1)[31,32]. Dynamic contrast-enhanced MRI
(DCE-MRI) is a technique sensitive to alterations in
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vascular permeability and blood flow. It has been
reported as a sensitive imaging method for the evaluation
of response to chemotherapy and it might help in differ-
entiating viable tumour from vascularised granulation
tissue[13,33]. It is, however, not widely used in clinical
practice, as it is labour intensive and technically challen-
ging[34]. These approaches incorporate an increasingly
popular concept of imaging; i.e. it is not (only) size
that matters, but more so the underlying tissue function,
cell biology, physiology and biochemistry.
Positron emission tomography
Positron emission tomography (PET) is a technique with
large potential because of its ability to image biological
characteristics based on the differential utilisation of var-
ious substrates by cancer cells and normal tissue.
Numerous PET radiopharmaceuticals are available, but
the most widely used agent is [18F]fluorodeoxyglucose
(FDG). This lead position is in part due to its approval
as a tracer by the US Food and Drug Administration
(FDA) for routine clinical use[35], its early development,
and wide availability[36]. There is a clear rationale for
its use. Mammalian cells depend on glucose as a
major source of energy and of carbons. Glucose is trans-
ported into the cell via facilitative transporters (GLUT)
present in all cell types. Many GLUT isoforms exist with
tissue-specific expression, subject to environmental con-
trol (e.g. hypoxia)[37]. After membrane transport, glucose
is phosphorylated by hexokinases to glucose 6-phosphate
and is further metabolised in the glycolysis pathway.
Increased glucose utilisation of malignant cells has
been recognised for decades. Like glucose, FDG is trans-
ported into the cell cytoplasm where it is phosphorylated
and becomes trapped inside the cell as dephosporylation
hardly occurs.
Another well-characterised radiopharmaceutical is
[18F]fluorodeoxythymidine (FLT)[3840]. FLT is a pyri-
midine analog that utilises the salvage pathway of DNA
synthesis. Much like FDG, it is taken up through
Figure 1 Patient with liver metastasis from gastric GIST. Top, PET; middle, contrast-enhanced diagnostic CT; bottom,
fused images. After 18 days of imatinib there was a complete metabolic response on PET, while CT showed stable
disease according to RECIST (15%) and partial response according to Choi et al.[32].
Tuesday 7 October 2008 S63
facilitated transport and diffusion and phosphorylated by
a cell cycle-regulated enzyme, thymidine kinase 1 (TK1)
and then becomes trapped in the cell. TK1 activity is
higher in malignant cells than in normal cells; therefore,
the uptake of FLT is a reflection of proliferative activ-
ity[41]. Recent data indicate that the sensitivity to detect
most tumour types is lower than that of FDG PET.
However, specificity could be higher since FLT does
not accumulate in inflammatory cells[42], although the
latter is not undisputed[43].
PET scans can be evaluated both qualitatively
(visual assessment) or (semi)quantitatively[44].
Qualitative assessment is more practical for clinical use,
but obviously less objective. Semiquantitative measure-
ments of maximum standardised uptake value (SUV),
average SUV and tumour-to-background ratio (TBR)
have all been used. In recent years a gradual replacement
of PET scans with hybrid PET-CT scanners has occurred.
PET in the various stages of
imaging in sarcoma
Grading and staging
In theory, increased FDG uptake represents a metaboli-
cally active site[4547]. Thus, PET scanning could
aid biopsy guidance and should discriminate between
sarcoma and benign conditions. However, non-malignant
processes like inflammation and areas with variable phys-
iologic FDG turnover such as brown fat and muscle may
interfere with image analysis[48]. The inherently limited
spatial resolution of PET compared to anatomical
imaging has been largely solved by using hybrid PET-
CT technology. Still, sensitivity for pulmonary and intra-
hepatic lesions may be relatively limited[4951].
To date, only one meta-analysis has been per-
formed[51], indicating that FDG-PET can indeed discrim-
inate between sarcomas and benign tumours and low
and high grade sarcomas, although the methodological
quality of the studies included was generally poor. Thus,
there is an urgent need for further evidence to support
the routine clinical use of FDG-PET for diagnosing and
staging sarcomas[52].
Treatment evaluation
The same principles that make FDG PET an interesting
new option in the diagnostic phase apply to evaluation
during treatment. Particularly, PET allows quantification
of tumour viability or proliferation. When listing
and evaluating studies that have investigated the value
of PET or PET/CT for therapy evaluation in sarcoma,
it becomes clear that there is no generally accepted def-
inition for a metabolic response in sarcoma on FDG-
PET. Preliminary criteria have been published by the
EORTC/RECIST group[53] and the National Cancer
Institute[54], but the imaging protocols, measures of activ-
ity and definitions of response have varied and study size
has been modest.
Bone sarcomas
Schulte et al.[55], Franzius et al.[56] and Nair et al.[57]
used TBR to determine metabolic response to neoadju-
vant chemotherapy in a total of 64 patients. In the first
Figure 2 (a) A patient with Ewings sarcoma of the left femur. Top, PET; middle, low-dose CT; bottom, fused images.
After two cycles of polychemotherapy PET showed (good) partial metabolic response while MRI showed stable
disease according to RECIST (16%). The resection sample showed only microscopic residue of viable tumour
(4 90% necrosis) and therefore correlated well with PET. (b) Axial contrast-enhanced spin echo T1-weighted MRI
image with fat-saturation acquired on the same day.
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two studies, the decrease of FDG uptake after chemo-
therapy correlated well with histological response. Nair
et al. found that tumour necrosis was accurately pre-
dicted on PET scan in 15/16 patients by visual assess-
ment, 14/15 patients by TBR value on presurgery scans,
and 7/15 patients using percent change of TBR on serial
scans. Hawkins et al. measured changes in the tumour
SUVmax in 69 patients and found a correlation with both
post-chemotherapy SUVmax and post- to pre-treatment
SUVmax ratio with histological response
[58,59]. Iagaru
implemented the RECIST criteria for PET analysis in a
heterogeneous group of bone and soft tissue sarcoma
patients in a protocol including both PET and PET/CT
imaging. The pathological degree of necrosis after
chemotherapy was concordant with PET in 57.1% of
cases; the observed discrepancies were attributed to
chemotherapy-induced inflammation. Inflammation
can be induced by radiotherapy and certain cytotoxic
agents[6062] sometimes presenting as the so-called
fibrous pseudocapsule with inflammatory tissue that
can form around the tumour[63]. Uptake in the latter
has been attributed to passive accumulation of FDG as
a result of altered cell membrane permeability in the ini-
tial phase of irreversible cell death[64].
For the detection of recurrent disease, Arush et al.[65]
and Gerth et al.[66] recently studied a total of 72 patients
including many Ewings sarcoma cases. The first study
confirms the high accuracy of FDG-PET/CT in the diag-
nosis of local relapse of sarcoma, while it failed in the
detection of metastases in three patients. Gerth et al.
compared PET and PET/CT and found that the sensitivi-
ty, specificity, and accuracy of single-modality PET were
71%, 95%, and 88%, respectively; the corresponding
values for the hybrid PET/CT technique were 87%,
97%, and 94% (P50.0001). PET/CT thus was signifi-
cantly more accurate than PET alone for the detection
and localisation of lesions.
Soft-tissue sarcomas
In this group of tumours, PET has been used to evaluate
not only chemotherapy effects, but also the effect of iso-
lated limb perfusion (ILP), a technique with the possibil-
ity of local high-dosed therapy to facilitate limb-sparing
surgery. For ILP, Nieweg and colleagues first reported a
case of liposarcoma in which PET suggested complete
response which was later confirmed by histological exam-
ination[67]. In larger groups of STS patients, it was shown
by Van Ginkel et al. that based on the pre-treatment
glucose consumption in soft-tissue sarcomas, one could
predict the probability of a patient achieving
complete response after ILP, although uptake in inflam-
matory tissue hampered the evaluation[68]. To overcome
this, PET with L-[11C]tyrosine was used by the same
group[69]. They were able to predict histological response
by post-treatment uptake rates and inflammatory tissue
did not interfere with viable tumour. More recently, a
study from this group investigated the possibilities of
FLT by PET/CT. Interestingly, uptake was correlated
with the mitotic index of the tumours (r¼ 0.82 and
P¼ 0.004 for SUVmax; r¼ 0.87 and P¼ 0.001 for
SUVmean). After HILP, the uptake of FLT decreased sig-
nificantly (P¼ 0.008 for SUVmax and P¼ 0.002 for
SUVmean). Tumours with initially high FLT uptake
showed a better response to HILP (r¼ 0.64,
P50.05)[41].
In the evaluation of chemotherapy, Jones et al.
described a homogeneously decreased FDG uptake
throughout the tumour in responsive cases. Again, despite
complete necrosis, persistent tumour FDG uptake was
observed in fibrous pseudocapsules[63]. Shields describes
two patients who underwent chemotherapy; in the
responding patient a decrease of FDG uptake of 40%
was seen while in the non-responding case uptake
increased by 69%. Change in [11C]thymidine incorpora-
tion was more marked in the responder but remained
stable in the non-responding case[70]. Changes in
tumour SUVmax predicted outcomes in 46 patients
with localised extremity STS by PET scanning in a
study by Schuetze et al.[36]. Not only was a change in
SUVmax 440% correlated with the amount of residual
viable tumour, also multivariate analysis found a correla-
tion between lack of response and increased risk of disease
recurrence, metastasis and death. Peng et al. confirmed
the association between permanent uptake and rapid
relapse versus decreased uptake and favourable response
in rhabdomyosarcoma[71], as did Kasper et al., by demon-
strating a significant difference in the progression-free
survival for patients with a decrease in the standardised
uptake value in comparison with patients with an
increased or stable SUV[72].
Hybrid PET/CT scanning has been performed in the
reports by Evilevitch et al. and Park et al.[35,73]. In the
Evilevitch study, FDG-PET was significantly more accu-
rate than size-based criteria (RECIST) at assessing
response to neoadjuvant therapy, correctly identifying
all of the responders and 71% of the non-responders
while only 25% of responding tumours were identified
by size-based criteria. Moreover, threshold values ranging
from 50% to 70% of baseline FDG uptake allowed assess-
ment of response, thereby limiting the effect of remaining
uptake in inflammatory lesions. Park et al. report that
PET or PET/CT was highly effective in discriminating
true recurrence in patients with suspected recurrence
and was highly sensitive in detecting recurrence in
asymptomatic patients.
Gastro-intestinal stromal tumours
The separate consideration of GIST from STS appears
rather artificial, but there are some distinct features to
FDG-PET in GIST. Comparability is better because the
same tumour under the same treatment regimen is stud-
ied and adherence to standardised response criteria[53]
has been rather strict. Also, directly from the first avail-
ability of imatinib for GIST treatment, it was shown that
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FDG-PET seems to predict response very early
(Fig. 1)[23,24,74] and therefore it has been incorporated
in a relatively large amount of study protocols, the larger
of which we have listed in Table 1. Overall results of
these studies have been that the main limitations are
the occasional lack of pre-treatment FDG avidity[31,75]
and the lower sensitivity for pulmonary and hepatic
lesions[76,77]. Still, all agree that PET scanning is a sen-
sitive and rapid indicator of response preceding size-
based response by weeks or months[23,74,7679].
Furthermore, response on PET scans is closely related
to clinical symptom relief[74] and predicts clinical
outcome[32,75,79].
FDG-PET in GIST exceeds the role of a staging and re-
staging modality. Different mutations with different ther-
apeutic impact can exist synchronously in a patient[81].
Furthermore, a change in micro-environment can result
in replacement of tumour cells with drug-resistant
variant cells[27,82,83]. In this context, FDG-PET-evalua-
tion can be used to select only progressive lesions for
resection in patients with ongoing response of the
remainder of the metastases[84], an approach that is
still controversial versus the generally accepted surgical
approaches in oncology.
Conclusion
Sarcomas have unique properties which not only increase
demands on imaging but also pose specific problems.
In the phase of diagnosis and staging, anatomical ima-
ging techniques such as MRI for local tumour character-
isation and CT for detection of pulmonary metastasis
remain indispensable and reliable techniques. During
treatment, the limitations of these techniques and their
size-based evaluation in sarcoma become clearer.
Although studies on the value of PET are of limited
size and quality, PET is a promising modality especially
for treatment evaluation in sarcoma, providing a rapid
and reliable indication of response. The possibility to
non-invasively detect tumour progression has already
influenced clinical practice in GIST in a revolutionary
way, with clear impact on patient management. PET
scanning has inherent limitations which fortunately do
not entirely overlap with those of anatomical imaging.
Therefore, these techniques should be regarded as com-
plementary. The studies comparing PET versus PET/CT
underscore this statement. For future studies, the avail-
ability of objective criteria for response evaluation with
PET would be highly instrumental to implement PET in a
cost effective way for patient tailored sarcoma treatment.
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